Tremfya rescues J&J’s immunology sales to fuel strong Q3
Johnson & Johnson (J&J) leaned on strong demand for anti-inflammatory drug Tremfya (guselkumab) to offset steep erosion in other areas…
News
Abram snags $8.3M US DoD contract to advance blood coagulation diagnostic
Steris outlays $2.1bn to acquire Xodus Medical
E2 wins FDA clearances for integrated Hēlo thrombectomy platform
Hiossen and GuidedSMILE collaborate on dental implant workflows
First patient treated in Spiro’s PULSAR asthma trial
Stryker invests $400m into CMR Surgical; secures future buyout option
Scarlet nabs $50m to grow AI-native medtech certification platform
